Publications by Judy Sebolt-Leopold

Publications by authors named "Judy Sebolt-Leopold"

Page 1 of 1

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).

Joseph S Warmus Cathlin Flamme Lu Yan Zhang Stephen Barrett Alexander Bridges Judy Sebolt-Leopold

Bioorg Med Chem Lett

December 2008

This paper reports a second generation MEK inhibitor. The previously reported potent and efficacious MEK inhibitor, PD-184352 (CI-1040), contains an integral hydroxamate moiety. This compound suffered from less than ideal solubility and metabolic stability.

View Article and Find Full Text PDF

Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.

Xue Wei Meng Joya Chandra David Loegering Keri Van Becelaere Timothy J Kottke Judy Sebolt-Leopold

J Biol Chem

November 2003

Article Synopsis

The MAPK pathway is crucial for cell growth and preventing cell death, making it a promising target for treatments in solid tumors and leukemia.
Researchers found that this pathway is consistently activated in various human lymphoid cell lines and about a third of acute lymphocytic leukemia (ALL) bone marrow samples.
Inhibiting the MAPK pathway with MEK inhibitors led to a specific form of cell death in ALL cells, revealing a mechanism that could be harnessed for new therapies against the disease.

View Article and Find Full Text PDF